ImpriMed Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 44

Employees

  • Latest Deal Type
  • Series A2

  • Latest Deal Amount
  • $10M

  • Investors
  • 31

ImpriMed General Information

Description

Developer of a personalized drug response prediction technology designed to offer vet information against lymphoma. The company's technology offers precision medicine techniques to allow veterinary oncologists to find appropriate anticancer drugs by building up a patient-derived database for pet cancer treatment which can be eventually translated into human cancer care, enabling doctors to decide on a final treatment regimen based on a data-driven prediction of response success in each patient body.

Contact Information

Website
www.imprimedicine.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3980 Fabian Way
  • Palo Alto, CA 94303
  • United States
+1 (650)
Primary Industry
Outcome Management (Healthcare)
Vertical(s)
Artificial Intelligence & Machine Learning, HealthTech, Life Sciences, Oncology
Corporate Office
  • 3980 Fabian Way
  • Palo Alto, CA 94303
  • United States
+1 (650)

ImpriMed Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ImpriMed Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC (Series A2) 18-Sep-2026 $10M Completed Generating Revenue
9. Accelerator/Incubator 19-May-2026 Completed Generating Revenue
8. Later Stage VC (Series A) 10-Nov-2023 Completed Generating Revenue
7. Accelerator/Incubator 01-Jan-2023 Completed Generating Revenue
6. Accelerator/Incubator 11-Aug-2022 Completed Generating Revenue
5. Seed Round 11-Mar-2021 Completed Generating Revenue
4. Seed Round 12-Apr-2019 Completed Startup
3. Accelerator/Incubator 25-Oct-2017 Completed Startup
2. Accelerator/Incubator Completed Startup
1. Accelerator/Incubator Completed Startup
To view ImpriMed’s complete valuation and funding history, request access »

ImpriMed Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A-2
Series A-1
Series A 8,582,136 $0.000100 $2.21 $2.21 1x $2.21 25.62%
Seed 10,592,896 $0.000100 $1.74 $1.74 1x $1.74 32.13%
To view ImpriMed’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

ImpriMed Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a personalized drug response prediction technology designed to offer vet information against lymphoma. The
Outcome Management (Healthcare)
Palo Alto, CA
44 As of 2025

Palo Alto, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ImpriMed Competitors (1)

One of ImpriMed’s competitors is FidoCure, a Venture Capital-Backed company based in Palo Alto, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
FidoCure Venture Capital-Backed Palo Alto, CA
You’re viewing 1 of 1 competitors. Get the full list »

ImpriMed Patents

  • 12

    Total Documents Applications and Grants

  • Total Patents Families

  • 7

    Granted

  • 2

    Pending

  • Expiring in next 12 mo

ImpriMed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026055154-A1 Treatment selection for personalized lymphoma treatment Pending 03-Sep-2024
WO-2023101037-A1 Machine learning-based method for predicting clinical outcomes or prognosis of anticancer therapy Inactive 30-Nov-2021
EP-4229214-A1 Methods and systems for predicting in-vivo response to drug therapies Active 14-Oct-2020
EP-4229214-A4 Methods and systems for predicting in-vivo response to drug therapies Active 14-Oct-2020
EP-4229214-B1 Methods and systems for predicting in-vivo response to drug therapies Active 14-Oct-2020 G16H50/20
To view ImpriMed’s complete patent history, request access »

ImpriMed Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ImpriMed Investors (31)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alois Ventures Venture Capital Minority
LB Investment Venture Capital Minority
NAVER D2SF Corporate Venture Capital
Samsung Securities Corporation
MedTech Innovator Accelerator/Incubator
You’re viewing 5 of 31 investors. Get the full list »

Ready to get started?

Request a free trial

ImpriMed FAQs

  • When was ImpriMed founded?

    ImpriMed was founded in 2017.

  • Where is ImpriMed headquartered?

    ImpriMed is headquartered in Palo Alto, CA.

  • What is the size of ImpriMed?

    ImpriMed has 44 total employees.

  • What industry is ImpriMed in?

    ImpriMed’s primary industry is Outcome Management (Healthcare).

  • Is ImpriMed a private or public company?

    ImpriMed is a Private company.

  • What is ImpriMed’s current revenue?

    The current revenue for ImpriMed is .

  • How much funding has ImpriMed raised over time?

    ImpriMed has raised $44.7M.

  • Who are ImpriMed’s investors?

    Alois Ventures, LB Investment, NAVER D2SF, Samsung Securities, and MedTech Innovator are 5 of 31 investors who have invested in ImpriMed.

  • Who are ImpriMed’s competitors?

    FidoCure is a competitor of ImpriMed.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process